Very early salvage radiation has up to fourfold better outcomes and saves lives

Another subject that has come up a lot recently is when to have salvage radiation. It is always a pressing decision for those 30 percent of prostatectomy patients who have detectable PSA after prostatectomy. … READ MORE …

Vasectomy and risk for prostate cancer (all over again)

As long-term readers will be aware, this is a topic that comes up over and over again … about every couple of years … READ MORE …

Hypofractionated radiation therapy using IMRT has a clear advantage

I was reticent to write about hypofractionation yet again after writing about it so often in the last year (see this link for my latest summary). … READ MORE …

Formal comment from ASTRO on the results of the ProtecT trial

The following official statement was issued on September 15 by the American Society for Radiation Oncology (ASTRO): … READ MORE …

Of moonshots, precision medicine, and progress in the management of cancer

As your sitemaster, let me be very clear about a couple of my most basic beliefs about prostate cancer and prostate cancer research. I want to do this because of all the recent media discussion about Vice President Byden’s “Moonshot” and the possible wonders of precision medicine. … READ MORE …

Patient-reported outcomes and quality of life in the ProtecT trial

We have already commented on the oncologic outcomes of patients enrolled in the ProtecT trial and published in today’s issue of the New England Journal of Medicine. In this commentary we shall comment on the separate paper that addresses patient-reported outcomes from that trial. … READ MORE …

The initial (10-year) results of the ProtecT trial: much as we might have expected?

So the majority of the readers of The “New” Prostate Cancer InfoLink will be well aware that we have never had data from a large, randomized clinical trial comparing the outcomes of the commonest first-line forms of management of men diagnosed with localized prostate cancer … READ MORE …